* ATEROVAX *
2006 - IDF
Paris
www.aterovax.com Discovery, Development, Diagnostics and Immunology-vaccines
Key words: Tests, Atherosclerosis, sPLA2 Activity Test, Atherosclerosis Risk Assessment, Biomarker for Cardiovascular Risk Evaluation and Prevention, Secreted Phospholipase A2 Activity, In Vitro Diagnostic Assay, Immunotherapy
Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis
Clients: undisclosed
contact@aterovax.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Surun (Dominique) [M.D., MBA (CPA), ex-Meda Pharma, Janssen Cilag, 3M]
Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.]
Fin.Dir.-CFO:
Regul.Dir.: Doceur (Paula) [Ph.D.]
BusDev:
Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€) | Turnover (M€) : 0.098 (2010)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cardiovasc
Position : 1st product soon available
Company confirm : 25-Mar-2010 |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .08 | Partnering distribution agreement for sPLA2 Activity Test with Biomnis (ex-Mérieux) | MKTG | [4 years] |
| 2010 .04 | Partnering distribution agreement for sPLA2 Activity Test in Europe with SPI-BIO (research use, only, for 3 years) | MKTG | [3 years] |
| 2009 .11 | Research : publication in European Heart Journal of Clinical of trial evaluating systemic sPLA2 association with prognosis in patients with coronary heart disease (1024 patients with CHD) | R&D | [3 years] |
| 2009 .11 | Clinical trial (phase III) for sPLA2 activity, as a stronger marker for risk prediction (ending) | CLIN | [3 years] |
| 2008 .07 | Financing : grant of 1.45 M€, by ANR, for the cardiovascular therapy program | RFIN | [2 years] |
| 2008 .06 | Prize : Siemens Innovation Price 2008 (Health) | MKTG | [2 years] |
| 2006 .07 | Seed financing : 3.0 M€ by SGAM (Specialized European Fund for Therapeutic Innovation) | SFIN | [0 year] |
| 2006 .06 | Company founded by Alain Tedgui, Ziad Mallat, and others, from Inserm exclusive worldwide rights to 3 filed patents covering current biomarker products and the immunotherapy program | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
